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Isosungucine (1) is a quasi-symetric bisindolomonoterpenoid alkaloid isolated from the roots of Strychnos icaja. 
The in vivo antimalarial activity against the P. vinckei petteri murine strain was determined. In the Peters 4-days 
suppressive test, 1 suppressed the parasitemia by almost 50 percent on day 4. 
 
 
Malaria is one of the major infectious 
diseases in many tropical and subtropical regions, 
leading to more than one million deaths (principally 
young African children) out of 400 million clinical 
cases each year. Since the end of the 1980s, 
Plasmodium falciparum has developed resistance 
almost everywhere in the world to chloroquine and 
other currently used antimalarial drugs [1,2]. 
Urgent efforts are therefore necessary to identify 
new classes of antimalarial drugs. 
 
Strychnos icaja Baillon (Loganiaceae) is a liana 
distributed all throughout central Africa and is the 
only African Strychnos species found to date to 
contain strychnine. Its roots were formerly used for 
the preparation of arrow and ordeal poisons [3]. 
However, some tribes of pygmies from Cameroon 

















Fig. 1 Chemical structure of isosungucine (1). 
 
The in vitro antiplasmodial properties of 
indolomonoterpenic alkaloids were described 
initially in 1991 by Wright et al., with the most 
active alkaloid being dihydrousambarensine, a 
bisindole tertiary alkaloid isolated from Strychnos 
usambarensis roots [6].  Among these bisindole 
antiplasmodial alkaloids, dihydrousambarensine 
and strychnopentamine were then tested in vivo 
against Plasmodium berghei but were inactive at a 
dose of 30 mg/kg/day [7]. Nevertheless, it was 
shown later that dihydrousambarensine was 25 
times more active against chloroquine-resistant 
strains than chloroquine-sensitive strains of 
Plasmodium falciparum. As the P. berghei strain 
used in this study was chloroquine-sensitive, this 
could explain the inactivity in vivo, in addition to 
the differences between the biology of the two 
species. Finally, in 2004, for the first time, the in 
vivo antimalarial activity of isostrychnopentamine, 
another indolomonoterpenic alkaloid, has been 
demonstrated against P. berghei  and P. vinckei [8].  
 
The in vitro antiplasmodial activities of 
isosungucine (1, Fig. 1) and its derivatives have 
been described previously [9]. The IC50 for 
isosungucine was 1.32 µM on FCA chloroquine-
sensitive strain and 0.27 µM on W2 chloroquine-
resistant strain. Compound 1 exhibited 7-35-fold 
higher activity against P. falciparum strains 
compared with human cancer cell lines (depending 
on Plasmodium strains and human cell lines), thus 
indicating a good selectivity [9]. Very recently, it 
was shown that the bisindole alkaloids from S. icaja 
possessing antiplasmodial properties were 
practically devoid of strychnine-like activity in 
vitro[10]. The objective of the present investigation 
was to demonstrate the in vivo antimalarial activity 
of isosungucine (1, Fig. 1), a dimeric 
indolomonoterpenic alkaloid from S. icaja.  
 
Fig. 2 In vivo antimalarial activity of isosungucine (1) on mice infected by Plasmodium vinckei petteri. Data are shown as mean ± SD of six 
mice per condition. The 4-days suppressive test was performed as described by Peters[12]. Mice were inoculated with trophozoites and were 
treated  2h later with drug or vehicle at the indicated dose. The injections were repeated daily for 3 days. The parasitemias were compared at 
days 2-3-4.  
 
 
Fig. 3 Survival curves for mice treated with isosungucine(1) 30 mg/kg, chloroquine (1,5 mg/kg) and vehicle (control). 
 
 
Oxygenated derivatives of 1, 18-hydroxy-
isosungucine and strychnogucine B, were more 
active and more selective than compound 1 [9,11], 
nevertheless these compounds were isolated in too 
small quantities to be evaluated in vivo.  
 
The in vivo antimalarial activity of 1 on P. vinckei 
petteri (chloroquine-sensitive) is presented in Fig. 
2. The procedure followed is the classical 4-days 
suppressive test of Peters [12] where the test 
compound is administered for four days to the 
malaria-infected mice. This procedure is proposed 
by the WHO as the first line primary screen for in 
vivo testing of potential antiplasmodial 
compounds[13,14]. At 30 mg/kg/day, parasitemia 
was reduced on day 2 by 75 % and on day 4 by 
47% and survival was increased of at least 24 
hours. Nevertheless, at day 7, only one mouse was 
still alive (0 in control and 4 in chloroquine group) 
(Fig. 3).  These results are encouraging because the 
ED50 values obtained from other plant extracts or 
purified constituents when tested for their 
antimalarial activity are often largely higher than 
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***   p =  0,00004 versus 
control 
** p = 0,00006 versus 
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In conclusion, 1 has an interesting antiplasmodial 
activity profile, both in vitro on various laboratory 
strains and in vivo against a chloroquine sensitive 
murine strain. Showing selectivity for Plasmodium 
cells compared to human cells [17], and exhibiting 
no cross resistance with chloroquine,  1 shows an 
original profile, clearly different from 
isostrychnopentamine [8] and could be a good lead 
for antimalarial therapy. It is now important to 
investigate the molecular targets affected by 1 to 
trigger Plasmodium death. Moreover, it would be 
very interesting to evaluate the potentialities of the 
oxygenated derivatives of 1 in animal models. This 
will need reisolation or (semi)synthesis of 
additional quantities of these compounds. 
 
Materials and Methods 
Chloroquine diphosphate (97%, Sigma C6628, 
Bornem, Belgium), was used as antimalarial 
reference. Isosungucine (1) was isolated from 
Strychnos icaja as previously described[11] and its 
purity was assessed by HPLC (> 95%). Stock 
solutions (1 mM) were prepared with 5% DMSO 
(final concentration for in vitro assays maximum 
0.5%). The roots of S. icaja were collected near 
Kasongo-Lunda (RDCongo). Voucher specimen of 
the plant (Duvigneaud H787) was deposited in the 
herbarium of the Pharmaceutical Institute, at Liège 
and in the herbarium of the Belgian National 
Botanical Garden, at Meise. Plasmodium vinckei 
petteri strain was provided by Prof P. Grellier 
(Museum National d'Histoire Naturelle, Paris, 
France). P. vinckei petteri was maintained in mice 
by syringe passage. Female Swiss mice (10 weeks 
of age, 20±2 g), obtained from Charles River 
(Charles River Laboratories, Brussels), were 
maintained under controlled conditions of 
temperature (22 ± 3 °C, relative humidity 50 - 80 
%) and illumination (12 h light, 12 h dark) and 
were provided with a standard diet and water. All 
animal husbandry and handling conditions were 
accorded to the Principles of Laboratory Animal 
Care and the Belgian Regulation ("Arrêté Royal du 
14 Novembre 1993 Relatif à la Protection des 
Animaux de Laboratoire"). The present work was 
approved by the Ethical Committee for using 
animals at the University of Liège (No 79). They 
were inoculated on day 1 intraperitoneally with 20 
µl of infected mice blood (parasitemia of about 
20%) diluted in physiological saline (50%). The 
treatment dose was given intraperitoneally 2 h 
after infection on day 1 and was repeated once 
daily for 3 days, as a "4-days-blood schizonticidal 
test" [12]. For this study, isosungucine was 
dissolved first with DMSO (final concentration: 
2%) and Tween 80 (final concentration: 2.5%) 
then in 0.9% sodium chloride with a volume of 
injection of 0.1 ml. For each drug, 6 mice were 
studied, and their parasitemia and mortality were 
followed. In parallel, 6 mice as control animals 
received only the vehicle (0.9% sodium chloride, 
DMSO, Tween, 0.1 ml, I.P.) and 6 mice received 
chloroquine (1.5 mg/kg). On day 2-3-4, thin blood 
smears were made from mouse tail blood and 
stained by Giemsa. At least 2000 cells were 
counted to determine parasitemia.  
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